<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570893</url>
  </required_header>
  <id_info>
    <org_study_id>ZTOG-1401</org_study_id>
    <nct_id>NCT02570893</nct_id>
  </id_info>
  <brief_title>A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, phase III trail comparing adjuvant&#xD;
      chemoradiotherapy (Paclitaxel and carboplatin) to adjuvant radiotherapy in patients&#xD;
      undergoing radical esophagectomy for pathologic lymph node positive esophageal squamous cell&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Population: Age: 18-70y; Thoracic esophageal squamous cell cancer undergoing radical&#xD;
      esophagectomy; Clinical stage T1-4, N1-3, M0; Eastern Cooperative Oncology Group (ECOG)&#xD;
      score: 0-1; The patients are randomized to 2 arms. Arm A: Adjuvant radiotherapy&#xD;
      (50.4gray/28fraction) followed by chemotherapy (Paclitaxel and carboplatin) 4 cycles. Arm B&#xD;
      :Adjuvant radiotherapy (50.4gray/28fraction) only&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the 3 years overall survival of two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the 3 years disease-free survival of two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Number and degree of Adverse Events based on Common Toxicity Criteria for Adverse Effects(CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the quality of life based on FACT-E</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant radiotherapy</intervention_name>
    <description>Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.</description>
    <arm_group_label>adjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant radiotherapy</intervention_name>
    <description>adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.</description>
    <arm_group_label>adjuvant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and carboplatin</intervention_name>
    <arm_group_label>adjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented squamous cell carcinoma of the thoracic esophagus;&#xD;
             undergoing radical esophagectomy; the pathological stage is T(primary tumor)1-4&#xD;
             N(regional lymph nodes)1-3 M(distant metastasis)0 (ESOPHAGUS, Union for International&#xD;
             Cancer Control(UICC) 2010) ;&#xD;
&#xD;
          2. Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy);&#xD;
&#xD;
          3. The expectation of life is more than 6 months;&#xD;
&#xD;
          4. Age: 18~70 years old;&#xD;
&#xD;
          5. Normal hemodynamic indices before the recruitment (including white blood cell&#xD;
             count&gt;4.0×109/L, neutrophil count&gt;1.5×109/L, platelet count &gt;100×109/L,&#xD;
             hemoglobin≥90g/l, normal liver/kidney function);&#xD;
&#xD;
          6. ECOG (Eastern Cooperative Oncology Group) : 0-1;&#xD;
&#xD;
          7. Able to understand this study and have signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have been treated with chemotherapy, radiotherapy and other anti tumor treatment&#xD;
             except surgery;&#xD;
&#xD;
          2. Known or suspected of allergy to paclitaxel or carboplatin;&#xD;
&#xD;
          3. Female in pregnancy or lactating;&#xD;
&#xD;
          4. With significant psychological, family, social and other factors which may affect the&#xD;
             ability to understand and sign the informed consent;&#xD;
&#xD;
          5. Patients with peripheral neuropathy(CTC grade≥2);&#xD;
&#xD;
          6. With other malignant tumors before the recruitment.&#xD;
&#xD;
          7. The researchers consider that the patient is not appropriate to enroll the study;&#xD;
&#xD;
          8. The patient can't be tolerant to postoperative adjuvant radiotherapy and chemotherapy&#xD;
             for serious heart/lung/liver/kidney function, the haematopoietic system diseases, the&#xD;
             immune system diseases, the nervous system diseases, cachexia and so on.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weimin Mao, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weimin Mao, MD.</last_name>
    <phone>+86-571-88122032</phone>
    <email>maowmzj1218@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Xu, MD.</last_name>
    <phone>+86-571-88122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin Mao, MD.</last_name>
      <phone>+86-571-88122032</phone>
      <email>maowmzj1218@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yaping Xu, MD.</last_name>
      <phone>+86-571-88122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal cancer;adjuvant therapy;chemotherapy;radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

